Promising therapeutic approach for metabolic liver diseases—researchers target enzyme related to fat metabolism
A MedUni Vienna study has identified a new approach to the drug treatment of metabolic liver diseases. In an experimental ...
Detroit Karmanos center unveils new device for treating liver cancer at home
It uses electromagnetic waves to target tumors and is available to patients for whom first- and second-line treatments have ...
FDA places its most serious warning on menopause drug due to risk of liver injury
The US Food and Drug Administration has placed its most serious warning — a so-called black-box warning — on a drug used to ...
Perthera Finds Survival Differences In Lung Vs. Liver Metastasis In New Study
MCCLEAN, VA, UNITED STATES, December 16, 2024 /EINPresswire / -- Perthera, the leader in AI-driven Precision Oncology Decision Support, has unveile ...
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development
Coherus BioSciences is expanding in immunotherapy while managing financial risks. Learn why CHRS stock may benefit from the ...
precisionmedicineonline5d
SABCS Studies Highlight Novel HER2 Therapies in Frontline Setting, HER2-Low, Brain Metastases
Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.
The American Journal of Managed Care5d
Treatment Combinations Based in Immune Checkpoint Inhibitors Provide Survival Benefits in CRC
Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...
Machine learning model predicts breast cancer treatment response
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either ...
Medindia5d
2024 SABCS|Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
On the morning of2, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS), RemeGen Co. Ltd. ("RemeGen") (9995.HK, 688331.SH) ...
Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer at ESMO IO 2024
Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver ...
AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease
Under the agreements, AmMax and MD Anderson will build upon preclinical discoveries made by MD Anderson researchers to evaluate the potential for AMB-066, which targets colony stimulating factor 1 ...